search
Back to results

Norepinephrine Weaning Guided by the Hypotension Prediction Index in Vasoplegic Shock After Cardiac Surgery (NORAHPI)

Primary Purpose

Vasoplegia, Shock, Norepinephrine

Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
norepinephrine weaning protocol
norepinephrine weaning protocol and guided by the HPI
Sponsored by
Centre Hospitalier Universitaire, Amiens
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Vasoplegia focused on measuring vasoplegia, shock, hypotension prediction index, Acumen, CABG, norepinephrine, surgery

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age > 18 years The patient was hospitalized in the cardiothoracic-vascular and respiratory intensive care unit of Amiens-Picardy University Hospital. Patient scheduled for on-pomp cardiac surgery [coronary artery bypass grafting, valve replacement, ascending aorta replacement, or combined surgery (valve and bypass grafting)]. Introduction of norepinephrine post-surgery for the treatment of vasoplegic syndrome. On-pomp cardiac surgery in less than 48 hours. Hemodynamically stable patient with MAP > 65 mmHg for more than 4 hours on noradrenaline Monitoring of MAP with a radial or femoral arterial catheter Social security beneficiary Signature of the consent to participate in the study by the patient, preoperatively Exclusion Criteria: Permanent arrhythmia (atrial fibrillation, flutter, or frequent atrial extrasystoles). Treatment with dobutamine, epinephrine, or vasopressin analog Patients with preoperative chronic end-stage renal failure require postoperative extra-renal purification. Pregnant woman The patient is dependent on an internal or external pacemaker. Hypothermia < 36°. Patient under mechanical circulatory assistance after cardiac surgery. Hemorrhagic shock Patient under guardianship or curators

Sites / Locations

  • CHU Amiens Picardie

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard care arm

Experimental arm (HPI-guided)

Arm Description

MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol

MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol and guided by the HPI (HPI<80) delivered by the Acumen IQ medical device.

Outcomes

Primary Outcome Measures

variation of the duration of norepinephrine administration between both groups

Secondary Outcome Measures

Number of norepinephrine protocol weaning failures
Number of norepinephrine protocol weaning failures, defined as persistent norepinephrine delivery 72 hours after the start of inclusion

Full Information

First Posted
June 20, 2023
Last Updated
July 11, 2023
Sponsor
Centre Hospitalier Universitaire, Amiens
search

1. Study Identification

Unique Protocol Identification Number
NCT05922982
Brief Title
Norepinephrine Weaning Guided by the Hypotension Prediction Index in Vasoplegic Shock After Cardiac Surgery
Acronym
NORAHPI
Official Title
Norepinephrine Weaning Guided by the Hypotension Prediction Index in Vasoplegic Shock After Cardiac Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 1, 2023 (Anticipated)
Primary Completion Date
June 2025 (Anticipated)
Study Completion Date
July 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire, Amiens

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In postoperative cardiac surgery under extracorporeal circulation, the patient may develop a vasoplegic syndrome, characterized by arterial hypotension (mean arterial pressure (MAP) < 65 mmHg); a decrease in vascular resistance and a cardiac output that may be normal or increased, and increased postoperative mortality/ International recommendations recommend the prescription of noradrenaline as a first-line treatment to reduce morbidity and mortality. However, excess norepinephrine or duration of exposure is also deleterious. The Acumen IQ device (Edwards Lifesciences) allows the calculation of a predictive index of arterial hypotension episodes (predictive hypotension index, HPI). HPI could improve norepinephrine weaning by preventing episodes of arterial hypotension or detecting preload dependence, thus avoiding the transient increase in norepinephrine during hypotension. This is a single-center, prospective, open-label, randomized, controlled, 2-group, parallel, intention-to-treat study. The aim was to evaluate the superiority of a new decision algorithm, based on the HPI delivered by the Acumen IQ device, to reduce the duration of norepinephrine administration in post-cardiac surgery vasoplegic shock. The duration of the interventional protocol is 72 hours. To evaluate the clinical impact of the protocol, the time of the study will be 30 days. Several follow-up visits will be performed (end-of-protocol day, discharge day, and at D30 of inclusion) to collect clinical, biological, and HPI monitoring data.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vasoplegia, Shock, Norepinephrine, Surgery
Keywords
vasoplegia, shock, hypotension prediction index, Acumen, CABG, norepinephrine, surgery

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
142 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Standard care arm
Arm Type
Active Comparator
Arm Description
MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol
Arm Title
Experimental arm (HPI-guided)
Arm Type
Experimental
Arm Description
MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol and guided by the HPI (HPI<80) delivered by the Acumen IQ medical device.
Intervention Type
Drug
Intervention Name(s)
norepinephrine weaning protocol
Intervention Description
MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol
Intervention Type
Drug
Intervention Name(s)
norepinephrine weaning protocol and guided by the HPI
Intervention Description
MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol and guided by the HPI (HPI<80) delivered by the Acumen IQ medical device.
Primary Outcome Measure Information:
Title
variation of the duration of norepinephrine administration between both groups
Time Frame
72 hours
Secondary Outcome Measure Information:
Title
Number of norepinephrine protocol weaning failures
Description
Number of norepinephrine protocol weaning failures, defined as persistent norepinephrine delivery 72 hours after the start of inclusion
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age > 18 years The patient was hospitalized in the cardiothoracic-vascular and respiratory intensive care unit of Amiens-Picardy University Hospital. Patient scheduled for on-pomp cardiac surgery [coronary artery bypass grafting, valve replacement, ascending aorta replacement, or combined surgery (valve and bypass grafting)]. Introduction of norepinephrine post-surgery for the treatment of vasoplegic syndrome. On-pomp cardiac surgery in less than 48 hours. Hemodynamically stable patient with MAP > 65 mmHg for more than 4 hours on noradrenaline Monitoring of MAP with a radial or femoral arterial catheter Social security beneficiary Signature of the consent to participate in the study by the patient, preoperatively Exclusion Criteria: Permanent arrhythmia (atrial fibrillation, flutter, or frequent atrial extrasystoles). Treatment with dobutamine, epinephrine, or vasopressin analog Patients with preoperative chronic end-stage renal failure require postoperative extra-renal purification. Pregnant woman The patient is dependent on an internal or external pacemaker. Hypothermia < 36°. Patient under mechanical circulatory assistance after cardiac surgery. Hemorrhagic shock Patient under guardianship or curators
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Christophe Beyls, MD
Phone
0322087866
Email
beyls.christophe@chu-amiens.fr
Facility Information:
Facility Name
CHU Amiens Picardie
City
Amiens
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christophe Beyls, MD
Phone
0322087866
Email
Beyls.Christophe@chu-amiens.fr
First Name & Middle Initial & Last Name & Degree
Osama Abou Arab, MD
First Name & Middle Initial & Last Name & Degree
Yazine Mahjoub, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Norepinephrine Weaning Guided by the Hypotension Prediction Index in Vasoplegic Shock After Cardiac Surgery

We'll reach out to this number within 24 hrs